Sofosbuvir: Completed Phase III enrollment

Gilead completed enrollment in the open-label Phase III ION-2 trial evaluating a once-daily, oral fixed-dose combination of 400 mg sofosbuvir plus 90 mg ledipasvir with ribavirin for 12 weeks and with or without ribavirin for 24 weeks in about 400 patients who failed prior therapy with pegylated interferon (IFN) or IFN plus a protease inhibitor. Gilead is also evaluating the fixed-dose combination of sofosbuvir plus GS-5885 with or without ribavirin in the Phase II LONESTAR trial in treatment-naïve and treatment-experienced patients and the Phase III ION-1 trial in 800 treatment-naïve patients with HCV genotype 1 infection. ...